TransCode Therapeutics Inc

TransCode Therapeutics is leading the way in bringing RNA therapies to oncology. Created on the belief that through the intelligent design and effective delivery to formerly undruggable RNA targets, TransCode is pioneering the development of therapeutics and diagostics to significantly improve patient outcomes.

Until now, RNA technology has been locked behind the challenge of delivery -- getting the RNA into the right cells and to their internal targets.

​TransCode Therapeutics believes it has overcome this barrier, opening the door to RNA therapy and applying it to cancer -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery vehicle for the transport of RNA therapeutics to targeted cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor types.

TransCode Therapeutics has created a platform of RNA drug candidates with the objective of improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually. ​Currently we are continuing research on a variety of both diagnostic and therapeutic approaches targeting biomarkers broadly prevalent across numerous tumor types. Additionally, TransCode’s other drug candidates, TTX-siPDL1, 64Cu-TTX-MC138, TTX-siLIN28b, TTX-RIGA, TTX-CRISPR and TTX-mRNA, focus on treating cancer using RNA technology made possible through our proprietary delivery platform.